|
Pronunciation |
|
(meth
skoe POL a
meen) |
|
|
U.S. Brand
Names |
|
Pamine® |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Methscopolamine Bromide |
|
|
Pharmacological Index |
|
Anticholinergic Agent |
|
|
Use |
|
Adjunctive therapy in the treatment of peptic ulcer |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Anticholinergic drugs decrease both esophageal and gastric motility and relax
the lower esophageal sphincter and are contraindicated in the presence of reflux
esophagitis; glaucoma; obstructed uropathy; obstructed disease of the GI tract
(pyloroduodenal stenosis); paralytic ileus; intestinal atony of elderly or
debilitated individuals; unstable cardiovascular status in acute hemorrhage;
severe ulcerative colitis; toxic megacolon; complicated ulcerative colitis;
myasthenia gravis; hypersensitivity to methscopolamine or related
drugs |
|
|
Adverse
Reactions |
|
>10%:
Dermatologic: Dry skin
Gastrointestinal: Constipation, xerostomia, dry
Respiratory: Dry nose
Miscellaneous: Decreased diaphoresis
1% to 10%: Gastrointestinal: Dysphagia |
|
|
Drug
Interactions |
|
No data reported |
|
|
Mechanism of
Action |
|
Methscopolamine is a peripheral anticholinergic agent that does not cross the
blood-brain barrier and provides a peripheral blockade of muscarinic receptors.
This agent reduces the volume and the total acid content of gastric secretions,
inhibits salivation, and reduces gastrointestinal motility. |
|
|
Usual Dosage |
|
Adults: Oral: 2.5 mg 30 minutes before meals or food and 2.5-5 mg at
bedtime |
|
|
Dietary
Considerations |
|
Should be administered 30 minutes before meals or food |
|
|
Mental Health: Effects
on Mental Status |
|
May rarely cause drowsiness, confusion, amnesia, or
nervousness |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
Concurrent use with psychotropics may produce additive sedation and dry
mouth |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
>10% of patients experience dry mouth; anticholinergic side effects can
cause a reduction of saliva production or secretion contributes to discomfort
and dental disease (ie, caries, oral candidiasis and periodontal
disease) |
|
|
Dosage Forms |
|
Tablet, as bromide: 2.5 mg |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|